Annual report pursuant to Section 13 and 15(d)

Significant Accounting Policies (Details Narrative)

v3.19.1
Significant Accounting Policies (Details Narrative)
12 Months Ended
Nov. 08, 2018
Dec. 31, 2018
USD ($)
Breathalyzers
shares
Dec. 31, 2017
USD ($)
Breathalyzers
shares
Reverse stock split On November 8, 2018, the Company effectuated a reverse stock split of its shares of common stock whereby every eight (8) pre-split shares of common stock were exchanged for one (1) post-split share of the Company's common stock ("Reverse Stock Split"). reverse stock split of its Common Stock at a ratio of eight-for-one (8-for-1).  
Restricted cash   $ 500,000
Maturities of securities   less than one year  
Unrealized loss on securities   $ 25,913 0
Marketable securities, gain   15,178 3,375
Allowances for doubtful accounts for trade receivables   606,835 596,196
Bad debt expenses   185,335 494,436
Trade receivables   176,326 964,671
Accrual for estimated sales returns   57,446 0
Accrued liabilities   23,179 126,471
Deferred revenue, recognized   105,247 296,164
Shipping, handling and transportation costs   1,538,285 2,406,132
Cost of net revenue   93,558 136,145
Net loss attributable to common shareholders   $ 10,849,034 $ 7,366,310
Weighted average basic and diluted common shares outstanding | shares   10,973,830 1,171,683
Shipping and Handling [Member]      
Shipping, handling and transportation costs   $ 50,518 $ 59,985
One Suppliers [Member]      
Concentration risk percentage   14.00%  
No Supplier [Member]      
Concentration risk percentage     10.00%
No Vendor [Member]      
Concentration risk percentage     10.00%
Sales Revenue, Net [Member]      
Concentration risk percentage   71.00% 73.00%
Concentration risk, number of customer | Breathalyzers   2 3
Sales Revenue, Net [Member] | Customer One [Member]      
Concentration risk percentage   57.00% 32.00%
Sales Revenue, Net [Member] | Customer Two [Member]      
Concentration risk percentage   14.00% 26.00%
Sales Revenue, Net [Member] | Customer Three [Member]      
Concentration risk percentage     15.00%
Trade Receivable [Member]      
Concentration risk percentage   73.00%  
Concentration risk, number of customer | Breathalyzers   2  
Trade receivables   $ 458,902 $ 111,037
Trade Receivable [Member] | Customer One [Member]      
Concentration risk percentage   59.00%  
Trade Receivable [Member] | Customer Two [Member]      
Concentration risk percentage   14.00%  
Trade Payables [Member]      
Concentration risk percentage   24.00%  
Trade Payables [Member] | Vendor One [Member]      
Concentration risk percentage   14.00%  
Trade Payables [Member] | Vendor Two [Member]      
Concentration risk percentage   10.00%  
Maximum [Member]      
Normal credit terms extended to customers   90 days  
Maximum [Member] | Patents [Member]      
Amortized over estimated useful life   17 years  
Minimum [Member]      
Normal credit terms extended to customers   30 days